Zosano Pharma

Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarkPulse, Inc.

Great Panther Silver

Ring Energy

Senseonics Holdings

Exela Technologies

Penny stocks are a great entry into the market. Here are seven that have the potential to provide quick returns with their strong catalysts.

7 Most Promising Penny Stocks to Achieve Your Multibagger Dreams

FREMONT, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achieving Therapeutic Concentrations of Triptans for the Treatment of Migraines.

Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine

Celsion

vTv Therapeutics

These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.

3 Biopharma Penny Stocks That Could be Millionaire Makers

ZSAN stock is zooming higher on Thursday after Zosano Pharma shared positive data on its proprietary migraine treatment. The post ZSAN Stock: Why Zosano Pharma Is Racing Higher Today appeared first on InvestorPlace.

ZSAN Stock: Why Zosano Pharma Is Racing Higher Today

Nano-cap Zosano Pharma Corporation (NASDAQ: ZSAN) has announced that long-term data for Qtrypta, as an acute treatment of migraine, published in The Journal of Headache and Pain. The tolerability and efficacy results in this long-term study were consistent with the results observed in the Phase 2/3 ZOTRIP study.

Zosano Stock Surges After New Study Shows Qtrypta's Potential As Long-Term Treatment Option For Migraine

The stock price of Zosano Pharma Corp (NASDAQ: ZSAN) increased by over 30% pre-market. This is why it happened.

ZSAN Stock Price: Over 30% Increase Pre-Market Explanation

FREMONT, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was published in The Journal of Headache and Pain . This open-label, multicenter observational study was designed to evaluate the safety and efficacy of the repeated use of Qtrypta™ in adults with migraine who had historically experienced at least 2 migraine attacks per month. The tolerability and efficacy results in this long-term study were consistent with the results observed in the Phase 2/3 ZOTRIP study.

Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain

FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad range of leadership roles across operations, strategic planning, manufacturing and supply chain management, quality and regulatory affairs and new product development.

Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors

FREMONT, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021, as well as business highlights.

Zosano Pharma Reports First Quarter 2021 Financial Results

Zosano Pharma Corporation is a late clinical-stage biopharmaceutical company developing rapid systemic administration techniques for two therapeutics using their proprietary transdermal microneedle system. The company is currently developing two therapeutics - one currently prioritized at the NDA stage (Qtrypta - proprietary formulation of zolmitriptan) for migraines which is resubmitting its NDA by 4Q 2021.

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Aeterna Zentaris

Micronet Enertec Technologies

As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch During the Last Week of April

180 Life Sciences 

Citius Pharmaceuticals

Jaguar Health

Ocugen, Inc.

Savara

Timber Pharmaceuticals

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

Lipocine

OrganiGram Holdings Inc.

SNDL Inc.

Liquid Media Group Ltd

Zomedica

Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.

7 Reddit Penny Stocks to Keep Your Eye on for Big Movement

FREMONT, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020, as well as business highlights.

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results

FREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Conference which will be available on Tuesday, March 9, 2021 at 7:00 am ET.

Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference

FREMONT, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration (“FDA") Division of Neurology II (the “Division”) regarding the requirements for resubmission of the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”) following the Complete Response Letter received on October 20, 2020.

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

Zosano Pharma (ZSAN) stock is flying high on Tuesday with heavy trading despite there being a lack of news about the company. The post ZSAN Stock: 9 Things to Know About Zosano Pharma as Shares Fly Higher appeared first on InvestorPlace.

ZSAN Stock: 9 Things to Know About Zosano Pharma as Shares Fly Higher

The stock price of Zosano Pharma Corp (NASDAQ: ZSAN) increased by over 100% this past week. This is why it happened.

ZSAN Stock Price Increased Over 100% This Past Week: Why It Happened

FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta™, Zosano's investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference.

Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines

Zosano Pharma (ZSAN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zosano Pharma (ZSAN) in Focus: Stock Moves 6.3% Higher

News that migraine-treatment maker Zosano Pharma will reapproach the FDA for approval has ZSAN stock jumping this morning. Investors should be cautious as penny stocks can cause big headaches.

ZSAN Stock: What Investors Should Know About Zosano Pharma

FREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on December 30, 2020 the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA).

Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application

FREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference that will be available on Monday, January 11, 2021 at 6:00 am ET.

Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference

LOS ANGELES--(BUSINESS WIRE)---- $ZSAN #ZSAN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Zosano Pharma Corporation.

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Zosano Pharma Corporation and Encourages Investors with Losses to Contact the Firm

New York, New York--(Newsfile Corp. - December 28, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Zosano securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's...

News for Zosano Pharma Stock (ZSAN)